Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers.
RESERACH TRIANGLE PARK, North Carolina-Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers. The trial, being conducted in collaboration with the Children’s Oncology Group, is expected to enroll up to 120 patients.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
2 Clarke Drive
Cranbury, NJ 08512